Evaluation of a novel accommodating silicone IOL concept: pharmacologically-induced effect 20 months after implantation

Session Details

Session Title: Cataract
Session Date/Time: Saturday 11/02/2017 | 08:30-11:00
Paper Time: 09:36
Venue: Auditorium 1

First Author: N. Hirnschall AUSTRIA
Co Author(s): R. Henson  J. Vincencio  A. Angeles  O. Findl  A. Phillips     

Abstract Details

Purpose:

To evaluate a novel concept of an accommodating 1-piece silicone IOL.

Setting:

Manila, Philippines

Methods:

All patients received a study IOL (Actalensﾙ, Emmetrope, La Canada, CA) in one eye and a control IOL (CrystaLensﾮ AO, B&L, USA, or a Acrysof IQﾮ, Alcon, USA) in the contralateral eye to allow for intra-individual comparison. At the 20months follow-up, two measurement days were set to measure all eyes before and after instilling 2% pilocarpine on the first day and 1% cyclopentolate and the second measurement day using an optical biometry device (Lenstar, Haag-Streit AG, Switzerland), respectively. PCO was graded by two examiners independently at the slit lamp.

Results:

In total, 16 eyes of 8 patients were included. In the study group and the control group the pilocarpine induced ACD shift was 0.32mm (SD: 0.12), (p=0.014) and 0.04mm (SD: 0.16), (p=0.854), respectively. In the study group and the control group, the mean cyclopentolate induced ACD shift was 0.14 (SD: 0.06) (p=0.014) and 0.03mm (SD: 0.03), (p=0.181), respectively. PCO and Nd:YAG rates were higher in the study group, but differences were not found to be significant (Acrysof vs Actalens p=0.100 and CrystaLens vs Actalens p= 0.174).

Conclusions:

The investigated IOL is a novel concept for an accommodating IOL and results showed a moderate pilocarpine induced forward shift of the IOL. Additionally, the investigated IOL seems to have a higher PCO rate compared to standard monofocal IOLs.

Financial Disclosure:

has significant investment interest in a company producing, developing or supplying product or procedure presented